{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=United+Therapeutics",
    "query": {
      "sponsor": "United Therapeutics",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 135,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=United+Therapeutics&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=United+Therapeutics&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T23:29:01.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01273922",
      "title": "Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Staphylococcal Infections",
        "Candidiasis"
      ],
      "interventions": [
        {
          "name": "NDV-3 investigational vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NovaDigm Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-01",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-05-22",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273922"
    },
    {
      "nct_id": "NCT07037836",
      "title": "Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD (Chronic Obstructive Pulmonary Disease)",
        "Hypoxemia"
      ],
      "interventions": [
        {
          "name": "Inhaled Treprostinil (Tyvaso Nebulizer)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bastiaan Driehuys",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-09-29",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037836"
    },
    {
      "nct_id": "NCT03626688",
      "title": "A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PAH",
        "Pulmonary Hypertension",
        "Pulmonary Arterial Hypertension",
        "Hypertension",
        "Connective Tissue Diseases",
        "Familial Primary Pulmonary Hypertension",
        "Vascular Diseases",
        "Cardiovascular Diseases",
        "Hypertension, Pulmonary",
        "Lung Diseases",
        "Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Ralinepag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 687,
      "start_date": "2019-01-24",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626688"
    },
    {
      "nct_id": "NCT01477333",
      "title": "Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "UT-15C SR",
          "type": "DRUG"
        },
        {
          "name": "Tyvaso Inhalation Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-10",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01477333"
    },
    {
      "nct_id": "NCT06388421",
      "title": "DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Hypertension Due to Lung Diseases and Hypoxia",
        "Pulmonary Hypertension",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Prospective study assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2025-01-23",
      "completion_date": "2030-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388421"
    },
    {
      "nct_id": "NCT01131845",
      "title": "The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension",
        "Renal Dysfunction"
      ],
      "interventions": [
        {
          "name": "UT-15C SR (treprostinil diethanolamine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-05",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2012-05-17",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01131845"
    },
    {
      "nct_id": "NCT04827056",
      "title": "Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder (AUD)",
        "Post Traumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg",
          "type": "DRUG"
        },
        {
          "name": "Ethanol Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "PTSD Reactivity Condition",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Alcohol Cue Reactivity",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "Pharmacotherapies for Alcohol and Substance Use Disorders Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-11-09",
      "completion_date": "2023-06-02",
      "has_results": false,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827056"
    },
    {
      "nct_id": "NCT04708782",
      "title": "Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Treprostinil Ultrasonic Nebulizer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 598,
      "start_date": "2021-06-01",
      "completion_date": "2026-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708782"
    },
    {
      "nct_id": "NCT00439946",
      "title": "Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Crono Five ambulatory pump",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2007-02",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • New York, New York • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439946"
    },
    {
      "nct_id": "NCT01996254",
      "title": "Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post-Amputation Pain",
        "Phantom Limb Pain",
        "Residual Limb Pain"
      ],
      "interventions": [
        {
          "name": "SPRINT Peripheral Nerve Stimulation (PNS) System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "SPR Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2013-10",
      "completion_date": "2019-01-28",
      "has_results": true,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-10-10T23:29:01.526Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01996254"
    }
  ]
}